MD vs THC: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: MD is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MD and THC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MD and THC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Pediatrix Medical Group (NYSE: MD), founded in 1979 and known as MEDNAX until its 2022 rebrand, provides hospital-based physician staffing and clinical services concentrated in neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and related anesthesiology support. Its clinicians largely staff neonatal intensive care units and other hospital departments under contracts with hospital partners, with revenue driven by patient volumes, payer reimbursement, contract administrative fees and revenue-cycle collections.

Full MD guide

Tenet Healthcare is a diversified for-profit healthcare services company that operates through three segments. Hospital Operations runs acute care and specialty hospitals plus affiliated outpatient facilities, imaging centers, and physician practices. United Surgical Partners International (USPI) is the ambulatory segment and operates or holds interests in hundreds of ambulatory surgery centers and surgical hospitals across dozens of states, making it the largest ASC platform in the country. Conifer Health Solutions provides revenue cycle management and value-based care services to hospitals and health systems.

Full THC guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• MD drivers: Pricing and reimbursement strength; Portfolio simplification and debt paydown.
• THC drivers: USPI ambulatory surgery leadership; Business mix shift toward higher-margin services.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Portfolio restructuring and practice divestitures continue to pressure headline revenue and narrow revenue diversification in a sector with several large, well-capitalized competitors. For THC, hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick MD if you believe its drivers more; THC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MD and THC guides.

MD. Pediatrix trades at a low-teens price-to-earnings multiple, well below the roughly 20x-plus average for healthcare-services peers, which reflects modest growth expectations and restructuring drag. Q1 2026 revenue rose about 4% year on year to roughly $476 million while diluted EPS improved to about $0.36 from $0.24. Full-year adjusted EBITDA is guided near $290 million at the midpoint.

THC. Tenet trades at a modest earnings multiple typical of hospital operators, reflecting reimbursement and leverage risk, but the multiple has expanded from prior years as USPI mix shift, margin gains, and deleveraging improved earnings quality. The 2026 outlook calls for net operating revenue of roughly $21.5 to $22.3 billion. Figures are approximate and drawn from reported results and company guidance as of mid 2026.

Headline figures (approximate, July 2026): MD shows revenue (ttm) ~$1.93B, q1 2026 net revenue ~$476M, net margin (ttm) ~9%, p/e ratio ~12x; THC shows revenue (ttm) ~$21.4 billion, fy2025 net operating revenue ~$21.3 billion (up ~3.7%), fy2025 adjusted diluted eps ~$16.78 (up ~41%), ebitda margin ~22-23%.

MD and THC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MD and THC exposure against your real portfolio. It is not an investment adviser.